Epigenetic silencing of WNT/β‐CATENIN antagonists is frequently observed in breast cancer, and reduced expression of APC, CDH1, SFRP1 and SFRP2 due to promoter hypermethylation has been reported in many breast tumours.49, 50. Here, SFRP1 is linked to breast neoplasm.